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We examined whether apolipoprotein E (APOE) status interacts with vascular risk factors (VRFs) to
predict the progression of white matter hyperintensities (WMHs) on brain MRI scans over a speciﬁc
period of life in older age when the risk of dementia increases. At age 73 years, baseline VRFs were
assessed via self-reported history of diabetes, hypertension, smoking, and hypercholesterolemia, and via
objective measures of blood HbA1c, body mass index, diastolic and systolic blood pressure, and blood
high-density lipoprotein to total cholesterol (HDL) ratio. APOE e4 allele was coded as either present or
absent. WMH progression was measured on MRI over 3 years in 434 older adults, in a same-year-of-birth
cohort. APOE e4 carriers with either a self-reported diagnosis of diabetes (b ¼ 0.160, p ¼ 0.002) or higher
glycated hemoglobin levels (b ¼ 0.114, p ¼ 0.014) exhibited greater WMH progression, and the former
survived correction for multiple testing. All other APOE-VRF interactions were nonsigniﬁcant (binteraction
< 0.056, p > 0.228). The results suggest that carrying the APOE “risk” e4 allele increases the risk of greater
age-related WMH progression over the early part of the eighth decade of life, when combined with
poorer glycemic control. The interaction effect was robust to co-occurring VRFs, suggesting a possible
target for mitigating brain and cognitive aging at this age.
 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Brain white matter hyperintensities (WMHs) are a prevalent
MRI feature of healthy and pathologic states in older age and are
associated with important life outcomes (Debette and Markus,
2010; Kloppenborg et al., 2014; Lee et al., 2016; Longstreth et al.,
1996) and vascular risk factors (VRFs) such as hypertension, dia-
betes, smoking, obesity, and hypercholesterolemia (de Leeuw et al.,
2004; Dufouil et al., 2001; Prins and Scheltens, 2015; Wang et al.,chology, 7 George Square,
651 1771.
ipt.
Inc. This is an open access article2015; Wardlaw et al., 2014). Compared with cross-sectional WMH
volumetric measures, WMH progression shows a stronger relation
with important age-related functional changes (Prins and
Scheltens, 2015; van Dijk et al., 2008), and it is possible that
different VRFs are relevant at different ages (Zhang et al., 2015).
Hence, longitudinal studies with a narrow age range are essential to
identify the most pertinent VRFs at speciﬁc periods in life.
Alongside evidence of VRF-WMH associations, WMH herita-
bility is estimated at 55%e80% (Atwood et al., 2004; Carmelli et al.,
1998; Turner et al., 2004). Variation in the apolipoprotein E (APOE)
gene (which delivers essential lipids to neurons and is linked to
accelerated neurodegeneration Bu, 2009; Mahley and Rall, 2000),
is a plausible candidate to explain some of this heritability.
Possession of the e4 “risk” allele is associated with more WMHsunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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et al., 2014; Heise et al., 2011) and greater cognitive decline
(Bangen et al., 2013; Schiepers et al., 2012; Wisdom et al., 2011).
However, APOE was not associated with cross-sectional WMH load
in 2 large studies (Fornage et al., 2011; Paternoster et al., 2009).
Discrepancies between heritability estimates of complex disease
and the risk explained by the common genetic variants might be
due to interactions with VRFs (Manolio et al., 2009). Prior exam-
inations of APOE-VRF interactions involved cross-sectional white
matter measures across participants of a broad age range, yielding
inconsistent results (de Leeuw et al., 2004; Foley et al., 2014; Wang
et al., 2015).
The current study is the ﬁrst, to our knowledge, to test the
interactions between APOE e4 status and VRFs on longitudinal
WMH progression.
2. Materials and methods
2.1. Participants
Members of the Lothian Birth Cohort 1936 were initially 1091
older adults, most of whom took part in the Scottish Mental Survey
1947 when aged 11 years and were living in the Edinburgh and
Lothian areas of Scotland at the start of Wave 1 of testing
(at w70 years of age in 2004e2007; Deary et al., 2007, 2012). All
were White Caucasian and reported no diagnosis of dementia at
baseline. 488 participants attended brainMRI scans at bothWaves 2
and 3 (mean ages 72.65 and 76.36 years). Of these, 434 provided
blood for genotyping at Wave 1 and VRF data at Wave 2. The Multi-
Centre Research Ethics Committee for Scotland (MREC/01/0/56),
the Scotland A Research Ethics Committee (07/MRE00/58) and the
Lothian Research Ethics Committee (LREC/2003/2/29) approved use
of the human subjects in this study; all participants provided
written informed consent and these have been kept on ﬁle.
2.2. APOE status
Genotyping on the 2 polymorphic sites (rs7412 and rs429358)
that account for the e2, e3, and e4 alleles (Wenham et al., 1991) was
performed on genomic DNA, isolated from whole blood, using
TaqMan technology by the Wellcome Trust Clinical Research Fa-
cility Genetics Core, Western General Hospital, Edinburgh. An exact
test (Web Reference 1) conﬁrmed that the APOE genotypes were in
Hardy-Weinberg equilibrium (p ¼ 0.657).
2.3. Vascular risk factors
The World Heart Federation, UK National Health Service,
Framingham Heart Study, and the British Heart Foundation (Web
References 2-5) overlap in their identiﬁcation of diabetes, hyper-
tension, smoking, high body mass index (BMI), and hypercholes-
terolemia as important VRFs and are pertinent to WMH burden in
older age (de Leeuw et al., 2004; Dufouil et al., 2001; Prins and
Scheltens, 2015; Wang et al., 2015; Wardlaw et al., 2014). VRFs
were assessed during a cognitive and physical testing appointment
at age 73 years. During a medical interview, diagnosis of diabetes,
hypertension, smoking (current, ex, or never), and hypercholes-
terolemia were reported. Objective VRFs were BMI (weight
kg/height m2), pulse pressure (difference between average systolic
and diastolic blood pressure, taken over 6 consecutive measure-
ments, 3 sitting and 3 standing, from an Omron 705IT monitor),
blood glycated hemoglobin (HbA1c using a Menarini HA8160
analyser), and the ratio of high-density lipoprotein to total
cholesterol (HDL ratio; Milián et al., 2009).2.4. MRI acquisition and processing
Whole brain MRI was performed on each participant at ages 73
and 76 years using the same scanning protocol in the same scanner
(GE Signa Horizon 1.5 T HDx; Milwaukee, WI, USA). T1-, T2-, T2*-,
and FLAIR-weighted sequences were coregistered at a resolution of
1  1  2 mm. A semi-automated multispectral fusion method
(Valdés Hernández et al., 2010) combined these sequences to
measure the intracranial andWMH volumes.WMHswere explicitly
deﬁned as punctate, focal, or diffuse lesions in all subcortical re-
gions (Wardlaw et al., 2013). All segmented images were visually
examined for accuracy on anonymized scans to correct errors and
ensure that infarcts (including lacunar infarcts, n ¼ 3 at baseline in
this sample) and enlarged perivascular spaces were excluded from
WMH masks. Full details are available in an open-access protocol
(Wardlaw et al., 2011).
2.5. Statistical analysis
WMH volumes at age 73 and 76 years were expressed as a pro-
portion of intracranial and corrected for age in days on the date of
image acquisition. Residuals of the regression between log WMH
volume at Waves 2 (IV) and 3 (DV) were derived to index WMH
volumechange (DWMH)over ameanof 3.71 (SD¼0.27) years. Using
the “sem” function in the “lavaan” package (v.0.5e22) in R v3.2.2, we
used DWMH as the dependent variable in models with VRFs and
APOE status (e4 allele present or absent) as predictors, alongside an
interaction term (APOE e4 status  VRF), for each VRF. We used full
information maximum likelihood estimation to reduce bias due to
missingness, under the assumption of “missing at random”
(Rubin, 1976), including the following “auxiliary” variables (previ-
ously used to model dropout in this cohort; Ritchie et al., 2016): age
11 IQ, years of education, father’s and own social class, Scottish Index
of Multiple Deprivation at recruitment, forced expiratory volume
over 1 second, 6-meter walk, hand grip strength (best of 6; 3 with
each hand), a binary variable indicating a self-reported diagnosis of
dementia or MMSE score <24 at any wave of testing (n ¼ 22). In
instances where interaction termswere signiﬁcant, coincident VRFs
were inserted as covariates. Standardized bs, corrected for false
discovery rate (FDR) are reported throughout. Variance inﬂation
factors (VIFs) among VRFs was ascertained using “vif” in the “usdm”
package for R. In a supplementary, a posteriori analysis, we further
explored interactions between APOE status and both HbA1c and
diabetes. We split APOE e4 and e2/3 groups by diabetes diagnosis or
high/low HbA1c level (median split at 5.59 DCCT), visualized, and
tested (t-tests) group differences in WMH progression.
3. Results
Participant characteristics are shown in Table S1, and density
plots of the raw and corrected measures ofWMH change are shown
in Fig. 1. There was a signiﬁcant increase in correctedWMH volume
in under 4 years (t (865.34) ¼ 3.685, p < 0.001) in the total sample.
Associations among the VRFs were modest (Table S2) and showed
low variance inﬂation factor (all <1.87). Exploratory factor analysis
provided no basis to extract 1 (c2¼ 164.8, p¼ 8.851025; 18.4% of
the variance) or 2 (c2 ¼ 59.96, p ¼ 5.33  108; 27.9% of the vari-
ance) factors of general vascular risk. A total of 136 participants
were APOE e4 carriers, who were not signiﬁcantly different to non-
e4 carriers in terms of age, cross-sectional WMH volume at either
wave,male:female ratio, MMSE score atWave 2, or VRF status. APOE
e4 carriers did, however, show a signiﬁcantly lower MMSE score at
Wave 3 (p ¼ 0.020, Table S1).
Effects of VRFs on WMH volume changedwithout reference to
APOEdhave previously been reported in this sample (Dickie et al.,
Fig. 1. Three-year white matter hyperintensity progression and group differences by APOE status and either diabetes or HbA1c. Kernel density plots of white matter hyperintensity
progression split by APOE status are shown for (A) raw uncorrected change in mm3, calculated by subtraction and (B) WMH change calculated as the residuals of the regression
between age 73 and 76 volumes, which were each log transformed and corrected for ICV and age at scan. A score of zero therefore denotes average WMH change in this and
subsequent panels. The group differences in corrected WMH change split by APOE status and (C) self-reported diabetes diagnosis and (D) HbA1c level are shown (lower panels).
Groups created from the whole sample based on a median split of HbA1c (Low range 4.4e5.59 DCCT, High range 5.60e8.9 DCCT), and APOE e4 status (carriers vs. noncarriers).
Brackets indicate signiﬁcant group differences at *p < 0.05, **p < 0.01, ***p < 0.001. Bold horizontal lines represent group means and vertical lines denote standard error.
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purposes, but the focus of the current analyses is speciﬁcally to
examine VRF-APOE interactions on WMH progression. Main effects
of APOE and VRFs on WMH volume change, and their interaction,
are reported in Table 1. APOE e4 carriers and thosewith a lower HDL
ratio showed nominally greater WMH progression than non-e4
carriers (b ¼ 0.118, p ¼ 0.014 and b ¼ 0.101, p ¼ 0.034, respec-
tively), but these did not survive FDR correction.
Participants with either a self-reported diagnosis of diabetes
(b¼ 0.160, p¼ 0.002) or higher HbA1c (b¼ 0.114, p¼ 0.014) showedgreater WMH progression, but only for APOE e4 carriers. Only the
interaction between APOE e4 and diabetes survived FDR correction.
Correcting these relationships for other, co-occuring VRFs (BMI,
hypertension, and hypercholesterolemia based on Table S2), did not
substantially alter the interaction effects for diabetes (b ¼ 0.167,
p < 0.001) and HbA1c (b ¼ 0.118, p ¼ 0.008). Further group-wise
analysis showed that participants with diabetes, or high HbA1c,
who carried the APOE e4 allele exhibited signiﬁcantly greater
change in WMH volume progression over 3.7 years than all other
groups (all t-values >2.34; Fig. 1).
Table 1
Main effects and interaction effects of APOE status in regressions between vascular
risk factor (VRF) and white matter hyperintensity change
Predictors of DWMH [VRF] [VRF]  APOE
b p b p
APOE 0.114 0.015
HbA1c 0.105 0.034 0.114 0.014
Diabetes 0.089 0.091 0.160 0.002
Body mass index 0.017 0.744 0.015 0.757
Pulse pressure 0.067 0.149 0.020 0.679
Hypertension 0.037 0.429 0.004 0.938
Smoking 0.043 0.403 0.024 0.633
HDL ratio 0.108 0.025 0.028 0.590
Hypercholesterolemia 0.002 0.974 0.056 0.228
Standardized betas reported.
Key: Diabetes, self-reported diagnosis of diabetes; HbA1c, glycated hemoglobin;
HDL ratio, ratio of high-density lipoprotein to total cholesterol; Smoking,
nevereex-smokerecurrent; DWMH, white matter hyperintensity volume change.
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The present study tested whether APOE status interacted with
important VRFs in contributing to WMH volume change from age
73e76 years in a large group of community-dwelling older adults
with a narrow age range. Our novel results suggest that WMH
growth was greater in those with diabetes and a higher HbA1c, but
only in those who possessed an APOE e4 allele, though only the
former interaction survived FDR correction.
The ﬁnding that APOE e4 is associated with WMH progression
extends previous cross-sectional associations between APOE status
and WMH volume in older age (Brickman et al., 2014; de Leeuw
et al., 2004; Wang et al., 2015). Rather than being an index of the
degree to which APOE status relates to accumulated WMH burden
up to a speciﬁc (single) point of assessment, the current data sug-
gest that carrying the e4 allele continues to inﬂuence the degree of
WMH progression at this speciﬁc age. In isolation, diabetes was not
associated with WMH progression (consistent with previous
studies; Prins and Scheltens, 2015), but, importantly, we found that
those with a current diagnosis of diabetes showed signiﬁcantly
greater WMH progression, but only if they carried the APOE e4
allele. The effect size was similar for an objective measure of gly-
cemic control, but this ﬁnding did not survive FDR correction. These
ﬁndings are consistent with prior associations between diabetes
riskeincluding glycemic control in “pre-diabetes”dand APOE allele
status for cognitive decline and dementia (Dore et al., 2009; Irie
et al., 2008; Peila et al., 2002; Roriz-Filho et al., 2009). Taken
together, this evidence provides support for the hypothesis that, as
with other complex diseases, genetic interactions are important for
understanding relationships between VRFs and WMH progression
in older age, and identifying potential targets for amelioration of
brain aging and dementia.
The duration, level, and success of medical intervention for VRF-
control in the current sample (such as statins for hypercholester-
olemia, antihypertensive, or antidiabetic medication) are unknown,
and may affect these ﬁndings. We also relied on self-report for in-
formation on a variety of clinical diagnoses. Nevertheless, the use of
blood biomarkers such as HDL ratio and HbA1c allow objective
measures, independent of self-report for some VRFs. More impor-
tantly, although the current total sample is relatively large, the
proportion of individuals with both diabetes and the e4 allele was
small, thus the speciﬁc diabetes-APOE interaction effect should be
tested independently. However, the presence of the same interac-
tion (with similar magnitude) with HbA1c might ostensibly
corroborate the biological plausibility of this result. Having only 2
waves of data makes our results more susceptible to artifacts suchas regression to the mean (see Nesselroade et al., 1980) and other
sources of bias such as measurement error. Our use of full infor-
mation maximum likelihood in this relatively large sample can only
guard against these possibilities to some degree. Finally, some
sample characteristics limit the conﬁdence with which these ﬁnd-
ings can be generalized to groups of different ages, ethnicities, and
pathologic states. Nevertheless, these sample characteristics can
also be viewed as study strengths, as they attenuate important
potential confounds of age, ethnicity, and the effect of infarcts on
WMHmeasurement, offering valuable insights into speciﬁc age and
interactions that might inﬂuence the progression of structural brain
damage.
The reduction of average blood glucose levels is identiﬁed here
as a potentially meaningful predictor of WMH progression in the
mid-1970s among APOE e4 carriers. This work requires replication
in other larger prospective imaging studies, and also at different
ages to examinewhether, andwhich, interactions contribute to life-
courseWMH volume changes. Furthermore, APOE is only one of the
many potential genetic contributors to WMH burden in older age.
Its consistent association with dementia and cognitive decline
make it an obvious candidate for interaction studies, but WMH risk
is likely to be polygenic (Lopez et al., 2015), and future studies
should examine other genetic-VRF interactions for predictingWMH
volume and progression.
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